Thursday, November 19, 2026
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO NA Magazine > Uncategorized > Pfizer and Biontech Expect to Have Omicron Variant Vaccine by March 2022

Pfizer and Biontech Expect to Have Omicron Variant Vaccine by March 2022

in Uncategorized
US Per Capita Carbon Footprint Looms Large
Share on LinkedinShare on WhatsApp

Pfizer and Biontech announced today that they expect to have a vaccine for the Omicron variant of Covid-19 by March 2022 if necessary to increase the level and duration of protection over it current vaccine.

The companies noted however that according to preliminary laboratory studies a third booster shot of its current vaccine neutralizes the new variant which has roiled the markets since its discovery in South Africa in November.

“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.

Meanwhile early reports from South Africa suggest that the variant has had little effect on the mortality rate in Gauteng province, the epicenter of the Omicron outbreak, despite a significant rise in the number of infections. Fatalities kept trending downwards through at the beginning of December despite explosive growth of the case rate from below 5 per 100,000 in the beginning of October to above 30 per 100,000 in the December.

“A significant early finding in this analysis is the much shorter average length of stay of 2.8 days for SARS-CoV-2 positive patients admitted to the COVID wards over the last two weeks compared to an average length of stay of 8.5 days for the past 18 months,” noted the latest report from the South African Medical Research Council.

By Feike de Jong

Tags: 2022BioNTechMarchOnmicronPfizerVariant

Related Posts

What Impact Investors Want from Companies with a Cause
Uncategorized

How purposeful innovation fuels growth for capital markets

The shift from oil isn’t just about being ‘green’ anymore. It’s a massive power move for national security.
Uncategorized

Oil jumps 5% after Trump dismisses Iran deal

Palantir stock surges after full-year results beat estimates
Uncategorized

Palantir rises 16% following 115% U.S. revenue increase

LG Energy Solution lands major U.S. battery storage deal
Uncategorized

LG Energy Solution lands major U.S. battery storage deal

Six Flags appoints new President and CEO, John Reilly
News

Six Flags appoints new President and CEO, John Reilly

Trump, Musk, Jensen Huang and Larry Fink attend US -Saudi Investment Forum
Uncategorized

Trilogy Metals shares explode 200% following Trump announcement

Trump praises Intel CEO following meeting
News

Nvidia to invest $5 billion in Intel

Canada – US relations may “never be the same again”
News

Canada – US relations may “never be the same again”

Primark’s CEO resigns from “error of judgment”
Uncategorized

Primark’s CEO resigns from “error of judgment”

Tips On Eating Healthy When Traveling
Food

Tips On Eating Healthy When Traveling

No Result
View All Result

Recent Posts

  • AI Has Entered the Boardroom. Who’s Overseeing It?
  • ‘Grand Theft Auto VI’ could be the biggest entertainment launch in history
  • Nvidia shares rally following earnings beat
  • Target reports its strongest sales growth in five years
  • Trump arrives in China for historic Xi, Putin meeting

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.